Completed NA INTERVENTIONAL 2-arm NCT04390477

Study to Evaluate the Effect of a Probiotic in COVID-19

The Intestinal Microbiota as a Therapeutic Target in Hospitalized Patients With COVID-19 Infection

Sponsor: Bioithas SL

Conditions COVID-19 Coronavirus Infection

Interventions Probiotic

Updated 7 times since 2020 Last updated: Apr 25, 2022 Started: May 4, 2020 Primary completion: Mar 21, 2021 Completion: Apr 30, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on COVID-19 and Coronavirus Infection, this trial is completed. The trial is conducted by Bioithas SL and has accumulated 7 data snapshots since 2020. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
May 2022 — Jul 2024 [monthly]

Completed NA
Sep 2021 — May 2022 [monthly]

Completed NA

Status: Recruiting → Completed
Feb 2021 — Sep 2021 [monthly]

Recruiting NA

▶ Show 2 earlier versions

Jan 2021 — Feb 2021 [monthly]

Recruiting NA
Jun 2020 — Jan 2021 [monthly]

Recruiting NA

First recorded

May 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bioithas SL

Data source: Bioithas SL

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Elche, Spain
• Torrevieja, Spain